why choose us

300×250 Ad Slot

Drug FDA Status

Showing 190 of 196 result(s) (Page 19 of 20)
Drug Name: Veozah

Active Ingredient: fezolinetant

Approval Date: 2023-05-12

Description: To treat moderate to severe hot flashes caused by menopause
Press Release

Drug Name: Elfabrio

Active Ingredient: pegunigalsidase alfa-iwxj

Approval Date: 2023-05-09

Description: To treat confirmed Fabry disease

Drug Name: Qalsody

Active Ingredient: tofersen

Approval Date: 2023-04-25

Description: To treat amyotrophic lateral sclerosis in adults who have a SOD1 gene mutation

Drug Name: Joenja

Active Ingredient: leniolisib

Approval Date: 2023-03-24

Description: To treat activated phosphoinositide 3-kinase delta syndrome

Drug Name: Rezzayo

Active Ingredient: rezafungin

Approval Date: 2023-03-22

Description: To treat candidemia and invasive candidiasis

Drug Name: Zynyz

Active Ingredient: retifanlimab-dlwr

Approval Date: 2023-03-22

Description: To treat metastatic or recurrent locally advanced Merkel cell carcinoma

Drug Name: Daybue

Active Ingredient: trofinetide

Approval Date: 2023-03-10

Description: To treat Rett syndrome

Drug Name: Zavzpret

Active Ingredient: zavegepant

Approval Date: 2023-03-09

Description: To treat migraine

Drug Name: Skyclarys

Active Ingredient: omaveloxolone

Approval Date: 2023-02-28

Description: To treat Friedrich's ataxia
Drug Trials Snapshots

Drug Name: Filspari

Active Ingredient: sparsentan

Approval Date: 2023-02-17

Description: To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression

300×250 Ad Slot